Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)
This study is currently recruiting participants.
Verified June 2012 by Johns Hopkins University
Sponsor:
Collaborator:
ALS Association
Information provided by (Responsible Party):
Nicholas Maragakis, MD, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01521728
First received: January 24, 2012
Last updated: June 6, 2012
Last verified: June 2012
| January 24, 2012 |
| June 6, 2012 |
| January 2012 |
| June 2014 (final data collection date for primary outcome measure) |
- Resistance Exercise Tolerability [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Evaluate the tolerability of RESISTANCE exercise in ALS subjects as measured by their ability to complete a 6 month study of a resistance exercise regimen.
- Endurance Exercise Tolerability [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Evaluate the tolerability of ENDURANCE exercise in ALS subjects as measured by their ability to complete a 6 month study of an endurance exercise regimen.
|
| Same as current |
| Complete list of historical versions of study NCT01521728 on ClinicalTrials.gov Archive Site |
- Vital Capacity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Evaluate the effect of resistance and endurance exercise on slow vital capacity (SVC)
- ALS Functional Rating Scores [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Evaluate the effect of resistance and endurance exercise on patients scores of the ALS Functional rating scale-revised (ALSFRS-R)
- Muscle Strength [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Evaluate the effect of resistance and endurance exercise on measures of muscle strength
- Spasticity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Evaluate the effect of resistance and endurance exercise on spasticity
- Fatigue [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Evaluate the effect of resistance and endurance exercise on fatigue
- Quality of Life [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Evaluate the effect of resistance and endurance exercise on patient quality of life
|
| Same as current |
| Not Provided |
| Not Provided |
| |
| Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) |
| Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) |
The first questions asked by patients with a new diagnosis of Amyotrophic Lateral Sclerosis (ALS) often include: "Does exercise help slow the progression of the disease?", "Is there any harm in exercising?", or "What type of exercise (endurance or resistance) is most appropriate?" At this time, however, there is a lack of answers for people who suffer from an illness that affects their strength above all else. Yet the beneficial effects of exercise in both healthy people as well as people with other diseases have been extensively studied and resulted in recommendations about the types of exercise that are beneficial. In this study the investigators will ask participants with ALS to exercise in one of three ways: weightlifting (resistance exercise), stationary bicycling (endurance exercise), and range of motion exercise (the current "standard of care" for ALS patients). The investigators will use several different types of tests to determine whether one type of exercise is tolerated better and is safer than another. The investigators will also collect information about how the body responds to exercise in ALS. This study will help in the development of a larger national study to understand how exercise can be combined with other treatments to potentially improve strength and alter the course of the disease. |
| Not Provided |
| Interventional |
| Not Provided |
Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Supportive Care |
| Amyotrophic Lateral Sclerosis |
- Other: Resistance Exercise
Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
- Other: Endurance Exercise
Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
- Other: Stretching/Range-of-Motion
Stretching and range of motion exercise is widely accepted as a "standard of care" for ALS management.
|
- Active Comparator: Resistance Exercise
Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
Intervention: Other: Resistance Exercise
- Active Comparator: Endurance Exercise
Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
Intervention: Other: Endurance Exercise
- Active Comparator: Stretching/Range-of-Motion Exercise
In ALS, stretching and range of motion are routinely recommended for the prevention of "frozen shoulder syndrome" and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a "standard of care" for ALS management.
Intervention: Other: Stretching/Range-of-Motion
|
| Not Provided |
| |
| Recruiting |
| 60 |
| June 2014 |
| June 2014 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Participants with familial or sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite according to the WFN El Escorial criteria
- Participants who are ages 18-80, inclusive.
- Slow Vital Capacity (SVC) must be equal to or greater than 70% of predicted value
- ALSFRS-R score >30.
- Patients who are currently on any medications must be on a stable dose for the past 30 days.
- Participants must provide informed consent prior to completion of any study procedures.
Exclusion Criteria:
- Participants who are already performing >30 min. of endurance exercise/day for ≥ 3x/week (Borg scale-- "hard" or "somewhat hard") within 30 days of screening.
- Participants who are already performing resistance exercise ≥ 3x/week within 30 days of screening.
Neurologic
- Patients participating in other ALS-related clinical drug trials
- Participants with history of ALS symptoms over 5 years duration
- Inability to obtain consent (psychiatric or dementing illness)
- History of neuromuscular dysfunction not related to ALS
Cardiac
- Patents with clinically significant ECG abnormalities
- Uncontrolled hypertension (SBP>160 or DBP>110)
- Recent history of angina (within the last 2 years)
- Recent history of abnormal stress test (within the last 2 years)
- Symptomatic severe aortic stenosis
- Active endocarditis
- Symptomatic heart failure
Respiratory
- Subjects with a history of respiratory dysfunction not related to ALS (i.e. COPD)
General
- Subjects with chronic infectious disease including HIV, hepatitis B or C.
- History of substance abuse within the past year
- Patients who have a history of poor compliance to medical regimens or study requirements.
- Uncontrolled diabetes
- Recent embolism (within the last 6 months)
- Severe orthopedic conditions that would prohibit exercise
Pregnancy
- Female subjects who are pregnant or planning to become pregnant.
- Female subjects of childbearing potential who are not practicing contraception.
Concomitant Medications
- Subjects who are taking more than 1000 IU of Vitamin C per day
- Subjects who are taking more than 400 IU of Vitamin E per day
- Subjects who are taking more than 600 mg of Coenzyme Q-10 per day
- Subjects who are taking more than 2 g of creatine per day
|
| Both |
| 18 Years to 80 Years |
| No |
|
|
| United States |
| |
| NCT01521728 |
| NA_00022650 |
| Yes |
| Nicholas Maragakis, MD, Johns Hopkins University |
| Johns Hopkins University |
| ALS Association |
| Principal Investigator: |
Nicholas M Maragakis, MD |
Johns Hopkins University |
|
|
| Johns Hopkins University |
| June 2012 |